Living with multiple sclerosis means living with uncertainty. The course of the disease is very difficult for doctors to predict. Some people live with MS for years without suffering serious symptoms. Others may rapidly become disabled. Why the course of the disease varies so widely remains unclear. One thing is certain. Most people with MS experience periodic relapses, also called flare-ups or attacks. These can be mild or severe. They may show up in many different ways. Symptoms can include:
- Muscle weakness
- Visual disturbances
- Balance problems
- Memory loss
- Loss of bowel or bladder control
“Between 85% and 95% of MS patients begin with what we call remitting/relapsing MS,” says Anne Cross, MD, professor of neurology at Washington University School of Medicine. During that phase of the disease, the pattern of relapses varies widely among patients. Some people have frequent relapses. Others have very few. The average is typically one to two attacks a year, according to Cross.
Doctors can help MS patients live as active and normal a life as possible by treating acute relapses as soon as they occur. Yet there are instances when doctors may recommend not treating a relapse.
Long-term and Short-term Treatment Strategies
Doctors follow two basic strategies in treating multiple sclerosis. To slow the long-term progression of the disease and reduce the frequency of flares, doctors prescribe “disease-modifying” agents. Doctors have many options to choose from, including interferon (Avonex, Betaseron, Extavia, and Rebif ), glatiramer acetate (Copaxone), mitoxantrone (Novantrone), teriflunomide (Aubagio), fingolimod (Gilenya), dimethyl fumarate (Tecfidera), and natalizumab (Tysabri).
Research shows that these disease-modifying drugs can decrease the rate of relapses by about 30%. They also lessen the severity of relapses. Not all forms of MS respond to these drugs, however. And even when the drugs work, they do not offer a cure. Most people continue to experience periodic relapses.
When acute attacks occur, doctors can suppress the underlying autoimmune damage, which is at the heart of MS, with the use of corticosteroids. Studies have shown that corticosteroid treatments significantly reduce the severity and shorten the duration of relapses for most patients. A typical dose is between 500 and 1,000 milligrams of intravenous methylprednisolone, which is gradually reduced over several weeks.
“But there is no clear-cut best way to administer corticosteroids, so doctors usually go on the basis of their own clinical experience with the disease,” says Ben W. Thrower, MD, medical director of the Andrew C. Carlos Multiple Sclerosis Institute at the Shepherd Center in Atlanta.